Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_001042432.2(CLN3):c.771G>T(p.Glu257Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar. Synonymous variant affecting the same amino acid position (i.e. E257E) has been classified as Benign.
CLN3 (HGNC:2074): (CLN3 lysosomal/endosomal transmembrane protein, battenin) This gene encodes a protein that is involved in lysosomal function. Mutations in this, as well as other neuronal ceroid-lipofuscinosis (CLN) genes, cause neurodegenerative diseases commonly known as Batten disease or collectively known as neuronal ceroid lipofuscinoses (NCLs). Many alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2008]
Loss of glycosylation at P259 (P = 0.0891);Loss of glycosylation at P259 (P = 0.0891);Loss of glycosylation at P259 (P = 0.0891);Loss of glycosylation at P259 (P = 0.0891);.;.;.;.;.;Loss of glycosylation at P259 (P = 0.0891);.;Loss of glycosylation at P259 (P = 0.0891);.;.;.;.;.;.;.;